These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 22176618)

  • 1. RAPID GENE trial marks the validation of the first point-of-care genetic test in clinical medicine.
    Harrison N
    Pharmacogenomics; 2012 Jan; 13(1):11-2. PubMed ID: 22176618
    [No Abstract]   [Full Text] [Related]  

  • 2. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.
    Roberts JD; Wells GA; Le May MR; Labinaz M; Glover C; Froeschl M; Dick A; Marquis JF; O'Brien E; Goncalves S; Druce I; Stewart A; Gollob MH; So DY
    Lancet; 2012 May; 379(9827):1705-11. PubMed ID: 22464343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bedside evaluation of thienopyridine antiplatelet therapy.
    Price MJ
    Circulation; 2009 May; 119(19):2625-32. PubMed ID: 19451364
    [No Abstract]   [Full Text] [Related]  

  • 4. Platelet inhibitors: update on clopidogrel (Plavix) and the recently approved prasugrel (Effient).
    Wynn RL
    Gen Dent; 2010; 58(1):7-9. PubMed ID: 20129886
    [No Abstract]   [Full Text] [Related]  

  • 5. High frequency of CYP2C19*2 carriers in PCI-treated patients switched over from clopidogrel to prasugrel based on platelet function monitoring.
    Bernlochner I; Mayer K; Morath T; Braun S; Schulz S; Schömig A; Koch W; Kastrati A; Sibbing D
    Platelets; 2013; 24(6):500-2. PubMed ID: 22916844
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost is not a barrier to implementing clopidogrel pharmacogenetics.
    Cavallari LH; Schumock GT
    Pharmacotherapy; 2012 Apr; 32(4):299-303. PubMed ID: 22461119
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
    Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
    Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stent thrombosis: who's guilty?
    Montalescot G; Hulot JS; Collet JP
    Eur Heart J; 2009 Nov; 30(22):2685-8. PubMed ID: 19854727
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to antiplatelet treatment: from genes to outcome.
    Giusti B; Abbate R
    Lancet; 2010 Oct; 376(9749):1278-81. PubMed ID: 20801497
    [No Abstract]   [Full Text] [Related]  

  • 10. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.
    Mega JL; Close SL; Wiviott SD; Shen L; Hockett RD; Brandt JT; Walker JR; Antman EM; Macias WL; Braunwald E; Sabatine MS
    Circulation; 2009 May; 119(19):2553-60. PubMed ID: 19414633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using models to predict the future: what to do when the data run out?
    Pauker SG; Goss FR
    Clin Pharmacol Ther; 2012 May; 91(5):769-71. PubMed ID: 22513311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping.
    Alexopoulos D; Dimitropoulos G; Davlouros P; Xanthopoulou I; Kassimis G; Stavrou EF; Hahalis G; Athanassiadou A
    JACC Cardiovasc Interv; 2011 Apr; 4(4):403-10. PubMed ID: 21511219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.
    Grosdidier C; Quilici J; Loosveld M; Camoin L; Moro PJ; Saut N; Gaborit B; Pankert M; Cohen W; Lambert M; Beguin S; Morange PE; Bonnet JL; Alessi MC; Cuisset T
    Am J Cardiol; 2013 Apr; 111(7):985-90. PubMed ID: 23340030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
    Saucedo JF; Angiolillo DJ; DeRaad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Duvvuru S; Effron MB;
    Thromb Haemost; 2013 Feb; 109(2):347-55. PubMed ID: 23223867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can we override clopidogrel resistance?
    Pena A; Collet JP; Hulot JS; Silvain J; Barthélémy O; Beygui F; Funck-Brentano C; Montalescot G
    Circulation; 2009 Jun; 119(21):2854-7. PubMed ID: 19487603
    [No Abstract]   [Full Text] [Related]  

  • 16. Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting.
    Sibbing D; Bernlochner I; Kastrati A; Paré G; Eikelboom JW
    Circ Cardiovasc Interv; 2011 Oct; 4(5):505-13; discussion 513. PubMed ID: 22010189
    [No Abstract]   [Full Text] [Related]  

  • 17. Prasugrel, Māori, and personalised medicine in New Zealand.
    Gladding P; White H; Webster M
    N Z Med J; 2010 Mar; 123(1310):86-90. PubMed ID: 20360782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Uhry S; Bessereau J; Camoin-Jau L; Paganelli F; Bonello L
    Hosp Pract (1995); 2012 Apr; 40(2):104-17. PubMed ID: 22615085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2C19 genotype-guided antiplatelet therapy in a patient with clopidogrel resistance.
    Rai M; Seip RL; Gupta A; McKay RG; Hirst J; Thompson PD; Ruaño G
    Conn Med; 2012 May; 76(5):267-72. PubMed ID: 22685981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel: a commentary.
    Madkour N; Bounthavong M
    Pharmacotherapy; 2012 Jun; 32(6):e170; discussion e170-1. PubMed ID: 22674743
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.